GHRP-6 — Clinical Reference

**⚠ Educational reference only — not medical advice.** This article is for research and educational reference. Always consult your own physician before considering any peptide protocol. See the full Disclaimer at the end of this article. ## Introduction GHRP-6 is a synthetic hexapeptide growth-hormone-releasing peptide developed alongside GHRP-2. Structurally similar to GHRP-2 but produces more pronounced appetite stimulation via the ghrelin pathway. Investigational; no approved indication in the United States. ## Mechanism of Action Agonist at the growth-hormone-secretagogue receptor (GHS-R1a). Receptor activation drives pulsatile GH release from anterior-pituitary somatotrophs and stimulates orexigenic centers in the hypothalamus. ## Research Indications Research overlaps with GHRP-2: GH-deficiency diagnostics, sarcopenia, cachexia, and recovery. The pronounced appetite effect makes GHRP-6 a candidate in cachexia and anorexia-of-aging contexts where weight gain is therapeutic. ## Reconstitution Typical 5 mg lyophilized vial: add **2 mL of bacteriostatic water**, swirl gently. Final concentration **2500 mcg/mL (2.5 mg/mL)** — each 0.04 mL (4 units on a U-100 insulin syringe) delivers 100 mcg. ## Dosing Protocol (research literature) Research protocols typically dose **100–300 mcg subcutaneously 1–3 times daily**, with the largest pulse pre-sleep. Common pairing with sermorelin or CJC-1295 (no DAC) at 100 mcg each, pre-sleep on empty stomach. Cycle length **8–12 weeks** with a **4-week off** period before re-cycling. ## Administration Subcutaneous into abdominal fat, rotating sites. Dose on empty stomach; pre-sleep dose 60–90 minutes after last food. The hunger effect peaks 30–60 minutes after injection. ## Storage & Handling Lyophilized: refrigerate (2–8°C). Reconstituted: refrigerate; stable approximately **21–28 days**. Protect from light. ## Side Effects Hunger (substantially more pronounced than GHRP-2), flushing, mild injection-site reaction, transient cortisol and prolactin elevation. Mild fluid retention at higher exposures. ## Contraindications Active malignancy, untreated proliferative diabetic retinopathy, pregnancy, lactation, uncontrolled diabetes, and any condition where appetite stimulation is undesirable. ## Monitoring Baseline IGF-1, fasting glucose, HbA1c, lipid panel; body weight and waist circumference for caloric-intake-relevant protocols. Re-measure IGF-1 at 6–8 weeks; reduce dose if trough IGF-1 exceeds the age-adjusted reference range. ## Disclaimer **This article is for informational and research-reference purposes only.** Nothing in this document constitutes medical advice, a prescription, or a recommendation from a physician. The reconstitution, dosing, and protocol information above reflects ranges commonly cited in published research and clinician-directed protocols — it is provided as reference material only, not as instructions, an endorsement of off-label use, or a substitute for individualized medical evaluation. **Customers should do their own research and consult their own physician** before considering any peptide protocol. Whether a given compound is appropriate for an individual — and at what dose, for what duration, and alongside what monitoring — is a decision that only a licensed clinician with knowledge of that individual's medical history, current medications, and conditions can make. The platform and the author make no claim that any compound described here is safe, effective, or appropriate for any particular person or purpose, and accept no responsibility for outcomes arising from self-directed use of the information.